Market Stakeholders Take Pit-Stop From The Immune Checkpoint Race

Posted: 04/28/2016

In order to examine the therapy which has been labelled as a game changing addition to oncology, earlier this month industry stakeholders met to explore the evidenced potential of immune checkpoint modulation therapies. The two day conference also saw attendees discuss and formulate tactics to scale the roadblocks encountered by the therapy. 

The immunogenicity of radiotherapies were assessed, looking at the modulation of the immune system against the cancer cells. This session established how solid tumors generate environments that suppress anti tumor immune responses and how radiotherapy can lead to early immunological changes in the tumor. It was noted that efficacy may be enhanced through combination with immunotherapy treatments.

One hurdle discussed was the wide range of potential protein combinations with immune checkpoint inhibitors. This saturation of options has caused many players to join the search to locate a formula for applying the right combined therapy to the right patient at the right time.

Interested in learning more about this topic?
Cell and gene
Download the agenda for Cell & Gene Manufacturing 2017

The race towards commercialisation of cell and gene products has already begun. Where technology innovations are pathing the way towards the development of these products, challenges surrounding scale up and closed system processing highlight areas that need our focus so that cell and gene therapy products can be produced on an industrial scale

The Cell and Gene Therapy Manufacturing Forum is the only conference that is 100% dedicated to focusing on development ofmanufacturing processes for these products. With presentations on improving cost efficiency, innovative strategies forcommercialisation as well as closed system processing, optimised manufacturing scheduling and maintaining GMP compliance, this forum is one that is not to be missed!

Topics on the agenda included, discoveries and findings from the first patient in a phase 1 clinical trial of immune oncology and alternative mechanisms of pd-1 down-regulation on t-cells in immunotherapy.

Companies represented at the event included Pfizer, Medimmune, Agonox, Apexigen, ImmuneGene and Prima Biomed.

In regards to the event’s value, Mark Coles, Chief Scientific Officer, Simomics said: “My key takehome is that clearly there are a lot of antibodies under development. There are very key differences between [those which] on the surface [are perceived] as very similar antibodies recognizing the same checkpoint target, [but can] potentially lead to different outcomes whether they be in mouse, primate models or in humans. So, understanding that so we have a better idea of how to develop optimal therapeutics going forward I think is going to be very important.”

Geert Mudde, Founder and CSO, OncoQR ML praised the level of science at the event, he noted - “I think is very important that people listen to each other, that they learn from each other and that they meet in an environment where it is pleasant to talk to one another.”

On the growing level of immunotherapies and the use of immune checkpoint inhibitors, Cancer Immunotherapy MarketResearch Report said:  “Either alone or in combination therapies, immunotherapies may produce long-term remissions or even cures for cancers that have been uniformly fatal until very recently. Thus immune-oncology is an important and rapidly emerging field, which deserves the attention it has been receiving in recent years.”

Video footage of April’s event is due to follow shortly. 

Posted: 04/28/2016

Pharma IQ Members


Crowne Plaza Zurich, Zurich, Switzerland
June 17 - 19, 2018